InterVenn
InterVenn Biosciences is a liquid biopsy company pioneering clinical glycoproteomic diagnostics using an AI- and ML-powered platform called GlycoVision™. Their technology enables precise quantification and characterization of glycoproteins, unlocking new biomarker discoveries for disease detection, progression, and therapeutic response. Founded in 2017 by Nobel Laureate Dr. Carolyn Bertozzi, Dr. Carlito Lebrilla, and AI expert Aldo Carrascoso, InterVenn partners with physicians, researchers, and biopharma to advance personalized medicine and improve patient outcomes. Their platform leverages liquid chromatography-tandem mass spectrometry and AI to analyze glycopeptides at scale, driving a robust pipeline of clinical applications in precision medicine.
InterVenn
InterVenn Biosciences is a liquid biopsy company pioneering clinical glycoproteomic diagnostics using an AI- and ML-powered platform called GlycoVision™. Their technology enables precise quantification and characterization of glycoproteins, unlocking new biomarker discoveries for disease detection, progression, and therapeutic response. Founded in 2017 by Nobel Laureate Dr. Carolyn Bertozzi, Dr. Carlito Lebrilla, and AI expert Aldo Carrascoso, InterVenn partners with physicians, researchers, and biopharma to advance personalized medicine and improve patient outcomes. Their platform leverages liquid chromatography-tandem mass spectrometry and AI to analyze glycopeptides at scale, driving a robust pipeline of clinical applications in precision medicine.